{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:34:54Z","timestamp":1783607694909,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Hair loss is a rare adverse reaction associated with omalizumab, with limited literature reports. The incidence, underlying mechanisms, and clinical characteristics of omalizumab-associated hair loss have not been clarified. We report a 52-year-old female with chronic spontaneous urticaria (CSU) who developed significant loss of eyebrows after 12\u202fweeks of omalizumab treatment at 300\u202fmg per 4\u202fweeks. The diagnosis of alopecia areata (AA) was confirmed through dermoscopic examination and clinical manifestation. While maintaining omalizumab treatment for CSU, topical 0.03% tacrolimus ointment was initiated for treatment of AA. Regrowth of eyebrows was observed at 28\u202fweeks of omalizumab treatment. We then performed a literature review, analyzing eight patients from five articles and one conference abstract, and concurrently analyzed data from 756 cases reported in the FDA adverse event reporting system (FAERS) database of patients developing alopecia after omalizumab use. Our findings suggest that omalizumab may induce alopecia, particularly among females and individuals aged 18\u201360\u202fyears. However, establishing a direct cause-effect relationship between alopecia and the drug remains challenging. AA may be the more uncommon type of omalizumab-associated hair loss, though it may be a transient phenomenon. Even if the incidence of this adverse effect is low, it warrants the clinician\u2019s attention. Improved recognition of omalizumab-associated hair loss can optimize pretreatment preparation and patient counseling.<\/jats:p>","DOI":"10.3389\/fmed.2025.1605826","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:31:45Z","timestamp":1751002305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4193\/Rhin21.159","article-title":"Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis","volume":"59","author":"Tsabouri","year":"2021","journal-title":"Rhinology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.alit.2017.10.001","article-title":"Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: subgroup analysis of the phase 3 POLARIS study","volume":"67","author":"Hide","year":"2018","journal-title":"Allergol Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1435370","DOI":"10.3389\/fmed.2024.1435370","article-title":"A comprehensive analysis on the safety of two biologics dupilumab and omalizumab","volume":"11","author":"Xiao","year":"2024","journal-title":"Front Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/14712598.2017.1285903","article-title":"Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety","volume":"17","author":"Gim\u00e9nez-Arnau","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000540104","article-title":"Drug-induced hair loss: analysis of the food and drug administration\u2019s adverse events reporting system database","volume":"11","author":"Hill","year":"2025","journal-title":"Skin Appendage Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","first-page":"205","article-title":"Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?","volume":"48","author":"Konstantinou","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.23822\/EurAnnACI.1764-1489.08","article-title":"Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab","volume":"49","author":"Noshela Ghazanfar","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2340\/00015555-3244","article-title":"Alopecia areata after omalizumab treatment for chronic spontaneous urticaria","volume":"99","author":"Magen","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/jocd.14507","article-title":"Transient alopecia areata following treatment with omalizumab in a patient with asthma and nasal polyps: a potential dermatological adverse event","volume":"21","author":"Jin","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e621","DOI":"10.1111\/ijd.16823","article-title":"A long-term course of alopecia areata during omalizumab treatment: a case report","volume":"62","author":"Miyamoto","year":"2023","journal-title":"Int J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.anai.2020.08.183","article-title":"A case of alopecia universalis possibly related to omalizumab","volume":"125","author":"Numair","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jaad.2023.04.022","article-title":"Medication-induced hair loss: an update","volume":"89","author":"Alhanshali","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00105-024-05352-5","article-title":"Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors: pathogenesis, clinical picture, diagnostics and prophylaxis","volume":"75","author":"Sachse","year":"2024","journal-title":"Dermatologie"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.annder.2020.08.043","article-title":"Erlotinib-induced scarring alopecia with a folliculitis decalvans-like presentation","volume":"147","author":"Dervout","year":"2020","journal-title":"Ann Dermatol Venereol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e8320","DOI":"10.7759\/cureus.8320","article-title":"Telogen effluvium: a review of the literature","volume":"12","author":"Asghar","year":"2020","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"103061","DOI":"10.1016\/j.autrev.2022.103061","article-title":"The current state of knowledge of the immune ecosystem in alopecia areata","volume":"21","author":"Connell","year":"2022","journal-title":"Autoimmun Rev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/ijd.17014","article-title":"A cross-sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system","volume":"63","author":"Ravipati","year":"2024","journal-title":"Int J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jdcr.2017.11.020","article-title":"Alopecia areata after dupilumab for atopic dermatitis","volume":"4","author":"Mitchell","year":"2018","journal-title":"JAAD Case Rep"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e2024270","DOI":"10.5826\/dpc.1404a270","article-title":"Dupilumab and alopecia areata: a possible combined or disturbance therapy? A review of the literature","volume":"14","author":"Starace","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jaad.2023.05.022","article-title":"Drug-induced alopecia areata: a systematic review","volume":"90","author":"Ezemma","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1038\/s41598-025-91463-5","article-title":"A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database","volume":"15","author":"Song","year":"2025","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/jocd.15558","article-title":"Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: a clinical and trichoscopic study","volume":"22","author":"Nassar","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1600-0625.1995.tb00256.x","article-title":"Mast cells as modulators of hair follicle cycling","volume":"4","author":"Maurer","year":"1995","journal-title":"Exp Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.3390\/ijms25115652","article-title":"Deciphering the complex immunopathogenesis of alopecia areata","volume":"25","author":"\u0160uti\u0107 Udovi\u0107","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/2229-5178.131076","article-title":"Total serum immunoglobulin E in patients with alopecia areata","volume":"5","author":"Bakry","year":"2014","journal-title":"Indian Dermatol Online J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1605826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:31:47Z","timestamp":1751002307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1605826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":33,"alternative-id":["10.3389\/fmed.2025.1605826"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1605826","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"article-number":"1605826"}}